1118 results about "Histone protein" patented technology

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

The invention discloses preparation of a human CD56 immune phage display antibody library, which comprises the following steps: S1, animal immunization: expressing recombinant hCD56 protein in escherichia coli, then immunizing a Balb / c mouse, and detecting immune titer; s2, splenocyte preparation: extracting RNA (Ribonucleic Acid) of immune mouse spleen cells, and performing reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid); s3, preparation of an initial bacteriophage display library: amplifying a heavy chain variable region and a light chain variable region by using a PCR technology, and then assembling to form scFv; constructing scFv phagocytids, electrically transforming the scFv phagocytids into TG1 competent cells, and constructing a bacterial library; s4, constructing a phage single-chain library of the hCD56: infecting the bacterial library by using a helper phage M13K07, and constructing a phage single-chain antibody library; and S5, elutriation and screening of a phage library: specifically enriching a phage single-chain antibody library, screening positive clones from the phage single-chain antibody library, and determining a sequence. According to the invention, the human hCD56 antibody scFv sequence fragment can be screened out, and the research and development period is shortened.

The invention belongs to the technical field of biomedicine, and discloses application of histone lactic acid modification as a target spot in preparation of a medicine for preventing or treating chronic obstructive pulmonary diseases, in particular to lactic acid modification on 18th lysine residues of histone 3, and the expression level of ATM protein in airway epithelial cells is up-regulated through the histone lactic acid modification, so that the chronic obstructive pulmonary diseases can be prevented or treated. The expression of cell senescence key genes is promoted, so that the senescence phenotype of airway epithelial cells is aggravated, and the airway epithelial cells participate in the disease process of mediating the chronic obstructive pulmonary disease. The discovery provides a new therapeutic target for the chronic obstructive pulmonary disease.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The present invention provides a monkey serum amyloid A recombinant protein, a monoclonal antibody and a preparation method and application thereof, wherein the amino acid sequence of the recombinant protein is shown in SEQ ID No. 1, and the nucleotide sequence encoding the recombinant protein is shown in SEQ ID No. 2. By optimizing the antigen peptide sequence and the expression vector, the efficient and soluble expression of monkey serum amyloid A in Escherichia coli is achieved, and a mouse monoclonal antibody specifically binding to monkey serum amyloid A is screened based on the monkey serum amyloid A recombinant protein, and the above mouse monoclonal antibody is used to screen a pairable monoclonal antibody, and further based on the monoclonal antibody combination, a double antibody sandwich immune ELISA detection method or kit applied to monkey serum amyloid A recombinant protein is obtained, which has high detection sensitivity and can be well applied to the detection of monkey serum.

The invention belongs to the field of veterinary drugs, and relates to an avian infectious bronchitis virus antigen recombinant protein S-Trimer and a subunit vaccine thereof. The invention provides an avian infectious bronchitis virus antigen recombinant protein S-Trimer. The amino acid sequence of the antigen recombinant protein S-Trimer is as shown in SEQ ID No. 4. The invention provides an infectious bronchitis virus antigen. The infectious bronchitis virus antigen is of a trimer structure of the recombinant protein S-Trimer. The invention provides a chicken infectious bronchitis virus subunit vaccine. The subunit vaccine comprises a pharmaceutically acceptable carrier and an immune dose of the chicken infectious bronchitis virus antigen. The vaccine is high in safety, good in immunogenicity and stable in batches, and can provide complete protection for attacking the infectious bronchitis virus.

The invention discloses a pertussis recombinant protein and a monoclonal antibody and application thereof.The pertussis recombinant protein is synthesized by selecting an S1 subunit of pertussis PT and a part of sequences of FHA protein, the pertussis recombinant protein is expressed through a prokaryotic expression system and purified, the protein serves as an antigen to immunize a mouse, and the pertussis recombinant protein is obtained. Positive hybridoma cell strains 3B10, 3D9 and 5F7 capable of stably secreting the antibody are obtained by adopting a hybridoma technology, the preservation numbers are respectively CCTCC NO: C202567, CCTCC NO: C202568 and CCTCC NO: C202569, and the obtained monoclonal antibody has relatively high affinity and detection sensitivity to pertussis PT and FHA recombinant proteins, is used for detecting a bordetella pertussis antigen, is strong in specificity and high in sensitivity, can be used for instant detection, and can be applied to clinical application. And the method has a relatively high application value.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention relates to the technical field of biology, and particularly discloses a recombinant protein for improving the curative effect of an ADC drug and application of the recombinant protein. The recombinant protein comprises a tumor cell surface targeting structure, a cell transmembrane structure and toxin molecules, the toxin molecule is connected and fused with the tumor cell surface targeting structure and / or the cell transmembrane structure; the tumor cell surface targeting structure is a protein structure capable of being specifically combined with a tumor cell surface target spot; and the cell penetrating structure is a protein structure for mediating the recombinant protein to penetrate through a cell membrane to enter the cell. The tumor cell surface targeting structure is used for specifically recognizing a target cell surface target spot, the killing activity of a conventional antibody is brought into play, then toxin molecules are brought into tumor cells through the cell transmembrane structure, toxin is released, the tumor killing effect is achieved, the ADC drug curative effect is improved, and the ADC drug application prospect is wide. The transmembrane efficiency of the cell transmembrane structure can be improved to 50-90%, so that the traditional ADC drug treatment window is improved.

The invention relates to the technical field of biological medicine, in particular to application of ADAMTS13 to occlusive cardiovascular and cerebrovascular diseases. On one hand, the invention provides the biomarker ADAMTS13 for establishing the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases, and the biomarker ADAMTS13 can be used as a target spot for diagnosing, preventing and treating the occlusive cardiovascular and cerebrovascular diseases and can effectively predict the establishment of the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases and prevent the development of adverse cardiovascular events; the method has important value on clinical cardiovascular events, and can improve the survival rate of patients with occlusive vascular diseases and improve long-term prognosis; on the other hand, the invention provides an ADAMTS13 recombinant protein, the amino acid sequence of which is as shown in SEQ ID No: 1, and the ADAMTS13 recombinant protein can improve the proliferation, migration, invasion and tube forming capabilities of endothelial cells, and has important clinical application value for developing drugs for preventing and / or treating occlusive cardiovascular and cerebrovascular diseases.

A composition comprising an expanded population of cells can be used in therapy, wherein the cells have been expanded by a method comprising: i) obtaining an isolated population of HSPCs; ii) culturing the isolated population of HSPCs in the presence of a histone deacetylase inhibitor (HDAC inhibitor) to form a cultured population; iii) adding to the cultured HSPC population an aminothiol compound having the formula RNH (CnH2n) NH (CnH2n) SX wherein R is hydrogen, an aryl group, an acyl group or an alkyl group containing from 1 to 7 carbon atoms, each n having a value of from 2 to 6, and X is H or PO3H2 to form expanded cells; or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of collagen, and discloses a preparation method of recombinant engineering bacteria for expressing III-type collagen COL17A1, which comprises the following steps: synthesizing an optimized sequence of human III-type collagen, and adding proper restriction enzyme cutting sites at two ends of the sequence. According to the preparation method of the recombinant engineering bacterium for expressing the III-type collagen COL17A1, codon optimization is carried out on a target sequence by adopting a yeast expression system, OptimGeneTM codon optimization is provided according to codon preference of yeast strains such as pichia pastoris, and the yield of recombinant protein is further improved. And a proper vector is selected to realize high-efficiency expression in pichia pastoris. For example, a pGAPZ A-alpha A vector stably expresses recombinant protein in pichia pastoris by using a GAP promoter, is a constitutive gene expression vector, and can maintain a stable expression rate in cells no matter how the environment changes. An inducer does not need to be added, the production process is simplified, the production cost is reduced, and the production efficiency is improved.

The invention discloses a swine fever and porcine parvovirus bivalent subunit vaccine and a preparation method thereof. The vaccine comprises a first recombinant protein encoded by a first gene, a second recombinant protein encoded by a second gene and a pharmaceutically acceptable carrier. The first gene has a sequence as shown in SEQ ID NO: 1 or an increased or reduced sequence thereof. And the second gene has a sequence as shown in SEQ ID NO: 2 or an increased or reduced sequence thereof. An antigen E2 protein of a hog cholera virus (CSFV) and a VP2 protein of a porcine parvovirus (PPV) are taken as double targets, a recombinant SC-E2 protein with a SpyCatcher tag and a recombinant ST-VP2 protein with a SpyTag tag are respectively expressed in insect cells through a recombinant baculovirus vector, double-antigen covalent assembly is realized in vitro, and the constructed bivalent subunit vaccine can be used for simultaneously preventing and controlling two epidemic diseases and has a good application prospect. And the vaccine has the advantages of high safety, strong immunogenicity, high prevention and control efficiency, easiness in large-scale production and the like.

Disclosed are a bispecific recombinant protein and a use thereof. The bispecific recombinant protein comprises a first functional binding region, a second functional binding region and an Fc region; the first functional binding region comprises a first chain and a second chain, and a C-terminus of the first chain and a C-terminus of the second functional binding region are separately connected to an N-terminus of the Fc region directly or by means of a linker sequence; and a C-terminus of the second chain is connected to an N-terminus of the second functional binding region directly or by means of a linker sequence. Further disclosed is an application of the recombinant protein in terms of anti-tumor, anti-virus, liver disease treatment, and other applications. The recombinant protein may significantly improve the killing efficacy of target cells while significantly reducing toxic side effects caused by binding to non-target cells, and has good safety and good freeze-thaw stability.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

The invention discloses a recombinant protein and application thereof in preparation of sodium alginate fibers. The recombinant protein is obtained by fusion expression of a functional protein and at least one alginic acid binding domain protein. The amino acid sequence of the alginic acid binding domain protein is as shown in at least one of SEQ ID No. 1, SEQ ID No. 2 and SEQ ID No. 3. The recombinant spider silk protein with the alginic acid CBM region can exert the material science characteristics in a sodium alginate-calcium ion system, the mechanical property of alginic acid fiber is greatly enhanced, and meanwhile, the biological activity of protein can be provided for an alginate fiber system.

The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and / or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

The invention relates to the technical field of aquaculture fish vaccines, in particular to a fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, a composition and application. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1. The fusion gene is obtained by connecting grass carp NPM1a and II type reovirus VP38 through a linker sequence, a BamH restriction enzyme cutting site is added to the 5'end of the fusion sequence, and an XhoI restriction enzyme cutting site is added to the 3 'end of the fusion sequence; the sequence of the linker is as shown in SEQ ID NO: 2. The subunit vaccine of the fusion protein of the grass carp NPM1a and the II type reovirus VP38 is prepared, and indole-3-lactic acid is used as an immunopotentiator in a combined manner, so that the technical bottlenecks of low protection rate, poor intestinal mucosal barrier repairability and the like of the existing vaccine are overcome.

Provided herein is a recombinant protein comprising a transmembrane domain derived from a transmembrane domain of a wild type erythropoietin receptor (EPOR). Nucleic acid molecules encoding such recombinant proteins, recombinant constructs, vectors and cells containing the nucleic acid molecules, methods of producing such cells and therapeutic uses thereof are also provided.

The invention belongs to the technical field of biological medicines, and relates to application of a PAPSS1 agonist and an endogenous protein sulfation modification up-regulating agent in preparation and screening of medicines for treating ischemic diseases. According to the application, the association between PAPSS1 up-regulation / excitation and histone sulfation modification mediated by PAPSS1 up-regulation / excitation and ischemic diseases is disclosed for the first time, and a new prevention and treatment thought is provided for ischemic cerebral apoplexy and other ischemic diseases.

Disclosed is use of a Histatin-1 polypeptide in promotion of cartilage regeneration or repair. By preparing a combined reagent containing a Histatin-1 polypeptide, a biological scaffold material and the like, mainly a linear Hst1 is loaded on gelatin methacrylate so as to be used for repairing cartilage damage or promoting cartilage growth; meanwhile, disclosed is use of a Histatin-1 polypeptide in promotion of the expression of one or more of bone differentiation indexes, including a collagen fiber, glycosaminoglycan, type II collagen and aggrecan.

The invention provides an antibiotic-free host-plasmid TA maintenance system and application thereof, and relates to the technical field of gene engineering. According to the invention, a toxin gene CcdB is accurately integrated to a host escherichia coli chromosome fhuA site through a gene editing technology, and accurate control of toxin expression is realized by adopting an inducible promoter. The antitoxin gene is simplified to a plasmid skeleton, and the toxin inhibition function is maintained through constitutive expression. According to the method, plasmid-free cells are eliminated through arabinose-induced toxin expression, so that stable maintenance of plasmids is realized (the loss rate is lt; and the method completely avoids the use of antibiotics, meets the biological safety requirements, is suitable for large-scale production of vaccines, recombinant proteins and other biological products, and has the advantages of high plasmid yield, low environmental leakage risk, process compatibility and the like.

The invention discloses a larimichthys crocea IL-22 recombinant protein which is a larimichthys crocea IL-22 mature peptide sequence, and the amino acid sequence of the larimichthys crocea IL-22 recombinant protein is as shown in SEQ ID NO. 2. The recombinant protein is obtained by amplifying and coding gene segments of amino acids from 31st to 190th positions of large yellow croaker IL-22 mature peptide through PCR (Polymerase Chain Reaction), and transforming escherichia coli for heterologous expression. The larimichthys crocea IL-22 recombinant protein can activate a transcription factor STAT3 in a larimichthys crocea head kidney cell line (LYCK) and also can induce expression of inflammatory factors (IL-1beta, IL-6 and IL-8) in immune organs of larimichthys crocea, so that the larimichthys crocea IL-22 recombinant protein has an obvious immunoregulation effect and shows a good application prospect in research and development of aquatic immunomodulators.

The invention discloses an application of beta-alanine in preparation of a medicine for treating pulmonary arterial hypertension. In-vivo and in-vitro pharmacological experiments prove that beta-alanine can inhibit lactic acid-mediated histone milk acylation modification and hypoxia-induced phenotypic transformation of PASMCs (Polyaspartic Sulfonate Molecules); the hemodynamics and pulmonary artery vascular remodeling of the PAH mouse are improved. The beta-alanine can inhibit phenotypic transformation of PASMCs and reverse pulmonary artery vascular remodeling which is a key pathological change in the pulmonary hypertension generation process, has huge potential in treatment of pulmonary hypertension, and has good application prospects and high clinical application value.

Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activity. Formulations and medicaments are also provided that are directed to the treatment of human disorders and conditions, such as, for example, neoplasms, cancers, viral, fungal, and parasitic infections, and aging. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

The composition is prepared from group B meningococcus NHBA recombinant protein, fHbp (V1-V1) recombinant protein and fHbp (V2-V3) recombinant protein obtained through artificial modification, or three corresponding recombinant proteins obtained by further adding P4 signal peptide on the basis of the group B meningococcus NHBA recombinant protein, the fHbp (V1-V1) recombinant protein and the fHbp (V2-V3) recombinant protein, and animal experiments prove that the composition has good immunogenicity and can be used for preparing the immunopotentiator. The compound can be used for preparing vaccines for preventing group B meningococcus.

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.

The present invention relates generally to glutamine-free cell culture media supplemented with arginine. The invention further concerns the production of recombinant proteins, such as therapeutic IgG antibodies, in a Chinese hamster ovary (CHO) host cell in a production phase culture medium that is essentially free of glutamine and comprises arginine in arginine.